Member Info for Timster

Agreed on both fronts RD.

And it's working for some patients where it wasn't expected to work, which is fantastic.

I wonder if any of the 2 week cohort are first line as Chris did say some might be in the last presentation.

Of course there is risk but the main risk is not the platform working it's whether AS blows all the money raised on something other than getting it to market.

And it works delivering 3.5 times a normal dose of dox with no dose limiting toxicity

He says it works and the next stage is to determine optimal dosing.

Timster, how'd you like that post yesterday calling you out for being a t*at getting so many recs

I cried myself to sleep last night atdb.

Oh by the way the pre|CISION platform works as intended and in the case of ava6000 it's delivering a chemo drug proven over 50 years. What don't you understand?

Ffs that twats carrying on where he left off yesterday. Read the RNS what does it say? What is pre|CISION designed to do?

It's clear as day (again) from today's RNS that it does exactly what it's designed to do.

Avct never moved on a positive RNS, at least not on the day of it, should start a steady rise though.

Now if there was also an ODX RNS we'd be flying!

He also said there was a news blackout

D-geeman:

The REX Offer was limited to an aggregate value of £6.8 million and received total applications in excess of this amount.

That's good news too.

@BV rereading, I think the running in parallel comment is a cohort in the US can run in parallel with a cohort in the UK. (Maybe)

Timescales for a trader would indicate there's no point jumping in yet.

For a longer view it's a great RNS

It was also mentioned yesterday:

CC is referring to slide 13: Toxicities with AVA6000 Demonstrate a Dose Relationship

“And so this table then describes for you a critical observation, as it provides then our first evidence that using a lower dose, and potentially shortening the interval between doses to every two weeks could enhance the anti-tumour activity by delivering more drug, increasing the dose intensity but with little to no severe toxicity. There are examples of this kind of approach in the clinic. Probably the most relevant here is the taxane Paclitaxel in the field of oncology. When Paclitaxel is administered in some settings in an every three-week regimen at a higher dose it's highly toxic, it's effective. However, when it was moved to an every weekly regimen with a lower dose, the toxicity was minimised and actually enhanced the activity. This weekly regimen is used more in the clinic, both are still used. But this is the rationale for these new dose cohorts of every two weeks dosing and it's based on the observations in this slide.”

https://youtu.be/eqj0hhgmX6U?si=tER5X1gdtec3L9Cd

Of course it can it's a platform, can be used for lots of drugs, however dox didn't need modification to work.

Other drugs may need analog versions which changes the whole approval landscape.

And still the twats continue the attempted FUD.

Read the RNS pre|CISION works as intended.

I read as phase 2 will be the single orphan indication, decided by the results of 1a and expansion phase.

Again, it works, it's there in black and white.

Bella , I'm going from what happened with my sister in law, it was breast cancer but she was given lots of options but stuck with "traditional" chemo and had an absolutely awful experience with the horrendous side effects.

He'd be given options of applicable trials from his physician when given the horrible prognosis.

Don't think he'd be applicable either for ava6k with dose expansion and phase 2 happening in America too it may not be an option in the UK soon.

What!!!! My 6 million USD will clear to my account tomorrow they told me.